ETHERNA IMMUNOTHERAPIES
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.
ETHERNA IMMUNOTHERAPIES
Industry:
Biotechnology Health Care Medical Device Therapeutics
Founded:
2013-01-01
Address:
Jette, Brussels Hoofdstedelijk Gewest, Belgium
Country:
Belgium
Website Url:
http://www.etherna.be
Total Employee:
11+
Status:
Active
Contact:
+32 3 369 17 40
Total Funding:
111.78 M USD
Technology used in webpage:
LetsEncrypt Apple Mobile Web Clips Icon Domain Not Resolving Apache Nginx Google Maps JsDelivr Cloudflare JS CDN JS ShareThis
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Passage Bio
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Spero Therapeutics
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections.
Current Advisors List
Current Employees Featured
Founder
Investors List
Fund+
Fund+ investment in Series B - eTheRNA immunotherapies
Novalis LifeSciences
Novalis LifeSciences investment in Series B - eTheRNA immunotherapies
Life Sciences Partners
Life Sciences Partners investment in Series B - eTheRNA immunotherapies
Omega Funds
Omega Funds investment in Series B - eTheRNA immunotherapies
Grand Pharma
Grand Pharma investment in Series B - eTheRNA immunotherapies
Kenneth Chien
Kenneth Chien investment in Series B - eTheRNA immunotherapies
PMV
PMV investment in Series B - eTheRNA immunotherapies
European Commission
European Commission investment in Grant - eTheRNA immunotherapies
Novalis LifeSciences
Novalis LifeSciences investment in Series B - eTheRNA immunotherapies
BNP Paribas Private Equity
BNP Paribas Private Equity investment in Series B - eTheRNA immunotherapies
Official Site Inspections
http://www.etherna.be Semrush global rank: 4.87 M Semrush visits lastest month: 1.81 K
- Host name: 199.60.103.82
- IP address: 199.60.103.82
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto
